- Shares of Twist Bioscience Corp (NASDAQ:TWST) fell after the firm issued fiscal second-quarter revenue guidance that fell below the consensus Wall Street estimate.
- For Q1 FY23, Twist posted a 29% increase in sales to $54.2 million, almost in line with the consensus of $54.1 million.
- The company shipped approximately 134,000 genes during the quarter to 2,060 customers, compared to about 1,800 customers during the year-ago quarter.
- For Q1, the company reported an EPS loss of $(0.74), down from $(0.91) a year ago compared to the consensus of $(1.13).
- Guidance: Twist Bioscience expects fiscal Q2 revenues of $56.5 million, below the consensus of $61.9 million, with $24 million in synbio revenues, $25 million in next-generation sequencing revenues, and biopharma revenues of $7.5 million.
- It anticipates full-year fiscal 2023 revenue of $261 million to $269 million, which remains unchanged.
- Price Action: TWST shares are down 16.6% at $25.77 on the last check Friday.
Amarin Announces Vascepa Approved To Reduce Cardiovascular Risk In Kingdom Of Saudi Arabia
-- VASCEPA® Approved in KSA To Reduce the Risk of Cardiovascular (CV) Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT--
